KR20070092307A - 로수바스타틴 제조 방법 - Google Patents

로수바스타틴 제조 방법 Download PDF

Info

Publication number
KR20070092307A
KR20070092307A KR1020077017101A KR20077017101A KR20070092307A KR 20070092307 A KR20070092307 A KR 20070092307A KR 1020077017101 A KR1020077017101 A KR 1020077017101A KR 20077017101 A KR20077017101 A KR 20077017101A KR 20070092307 A KR20070092307 A KR 20070092307A
Authority
KR
South Korea
Prior art keywords
group
protecting group
fluorophenyl
compound
isopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020077017101A
Other languages
English (en)
Korean (ko)
Inventor
마이클 버터스
스티븐 로버트 렌거
폴 마이클 머레이
에반 윌리엄 스네이프
Original Assignee
아스트라제네카 유케이 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34130901&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20070092307(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 아스트라제네카 유케이 리미티드 filed Critical 아스트라제네카 유케이 리미티드
Publication of KR20070092307A publication Critical patent/KR20070092307A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
KR1020077017101A 2004-12-24 2005-12-22 로수바스타틴 제조 방법 Ceased KR20070092307A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0428328.9A GB0428328D0 (en) 2004-12-24 2004-12-24 Chemical process
GB0428328.9 2004-12-24

Publications (1)

Publication Number Publication Date
KR20070092307A true KR20070092307A (ko) 2007-09-12

Family

ID=34130901

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077017101A Ceased KR20070092307A (ko) 2004-12-24 2005-12-22 로수바스타틴 제조 방법

Country Status (15)

Country Link
US (1) US8034932B2 (https=)
EP (2) EP1871747A2 (https=)
JP (1) JP5127460B2 (https=)
KR (1) KR20070092307A (https=)
CN (1) CN101084197B (https=)
AU (1) AU2005317880B2 (https=)
BR (1) BRPI0518647A2 (https=)
CA (1) CA2589775A1 (https=)
GB (1) GB0428328D0 (https=)
IL (1) IL183528A (https=)
MX (1) MX2007007777A (https=)
NO (1) NO20072872L (https=)
NZ (1) NZ555769A (https=)
WO (1) WO2006067456A2 (https=)
ZA (1) ZA200704535B (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011120D0 (en) 2000-05-09 2000-06-28 Avecia Ltd Process
NL1015744C2 (nl) 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
IL159741A0 (en) 2001-07-13 2004-06-20 Astrazeneca Uk Ltd Preparation of aminopyrimidine compounds
EP1323717A1 (en) 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
EP1375493A1 (en) 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
ES2335279T3 (es) 2002-12-16 2010-03-24 Astrazeneca Uk Limited Procedimiento para la preparacion de compuestos de pirimidina.
GB0312896D0 (en) * 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
EP1601658A1 (en) 2003-11-24 2005-12-07 Teva Pharmaceutical Industries Limited Crystalline ammonium salts of rosuvastatin
US7851624B2 (en) 2003-12-24 2010-12-14 Teva Pharamaceutical Industries Ltd. Triol form of rosuvastatin and synthesis of rosuvastatin
GB0428328D0 (en) 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
KR101020024B1 (ko) 2005-02-22 2011-03-09 테바 파마슈티컬 인더스트리즈 리미티드 로수바스타틴 알킬에테르를 함유하지 않는 로수바스타틴 및이의 염 및 이의 제조 방법
GB0514078D0 (en) * 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
EP1948618A1 (en) * 2006-09-18 2008-07-30 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin calcium
TW200831469A (en) * 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process
EP2134696B1 (en) 2007-04-03 2017-05-17 LEK Pharmaceuticals d.d. Processes for the preparation of statins, particularly rosuvastatin, and intermediates for the preparation thereof
EP1978020A1 (en) * 2007-04-03 2008-10-08 LEK Pharmaceuticals D.D. Processes for the preparation of statins, particularly rosuvastatin, and intermediates for the preparation thereof
EP2178847A2 (en) * 2007-08-20 2010-04-28 Ratiopharm GmbH Process for preparing pyrimidine derivatives
EP2181089A2 (en) 2007-08-28 2010-05-05 Ratiopharm GmbH Process for preparing pentanoic diacid derivatives
WO2010029561A1 (en) * 2008-09-09 2010-03-18 Biocon Limited A process for preparation of rosuvastatin acetonide calcium
CN105669561B (zh) * 2014-11-19 2018-11-27 南京博优康远生物医药科技有限公司 一种4-(4-氟苯基)-5-烷氧基羰基-6-异丙基-3,4-二氢嘧啶-2(1h)-酮的制备方法
MX368055B (es) * 2015-01-23 2019-09-18 Dsm Sinochem Pharm Nl Bv Procedimiento mejorado para preparar un precursor de estatina.
KR20160126700A (ko) 2015-04-24 2016-11-02 미래파인켐 주식회사 스타틴의 중간체, 이의 제조방법 및 이를 이용한 로수바스타틴의 제조방법

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US480621A (en) 1892-08-09 Oiler for handsaws
US4645858A (en) 1982-03-22 1987-02-24 G. D. Searle & Co. Pentanedioic acid derivatives
US4625039A (en) 1983-12-21 1986-11-25 Sandoz Pharm. Corp. 4-trisubstituted silyl protected hydroxy-6-oxo-tetrahydropyran-2-yl-aldehyde intermediates
US4650890A (en) 1984-04-03 1987-03-17 Sandoz Corp. Preparation of olefinic compounds and intermediates thereof
US4613610A (en) 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4677211A (en) 1984-06-29 1987-06-30 Sandoz Pharmaceuticals Corp. Preparation of lactones
US5102893A (en) 1986-07-07 1992-04-07 Warner-Lambert Company Trans-6-(2-(n-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl- or ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US4808621A (en) * 1986-07-07 1989-02-28 Warner-Lambert Company Trans-6-[2-(N-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl]- or ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
US4957971A (en) 1986-07-07 1990-09-18 Warner-Lambert Company Trans-6-(2-(N-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl)-or ethenyl)tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
DE3739882A1 (de) 1987-11-25 1989-06-08 Bayer Ag Substituierte hydroxylamine
DE3741509A1 (de) 1987-12-08 1989-06-22 Hoechst Ag Verfahren zur herstellung optisch aktiver 3-desmethylmevalonsaeurederivate sowie zwischenprodukte
DE3741508A1 (de) 1987-12-08 1989-06-22 Hoechst Ag Wasserloesliche disazoverbindungen, verfahren zu ihrer herstellung und ihre verwendung als farbstoffe
GB2244706B (en) 1988-02-18 1992-07-15 Bristol Myers Co Preparation of antihypercholesterolemic tetrazole intermediates
EP0367895A1 (en) * 1988-10-06 1990-05-16 Sandoz Ag Pyrimidinyl-substituted hydroxyacids, lactones and esters and pharmaceutical compositions containing them
FR2665159B1 (fr) 1990-07-24 1992-11-13 Rhone Poulenc Sante Nouveaux derives de la pyridine et de la quinoleine, leur preparation et les compositions pharmaceutiques qui les contiennent.
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
US5278313A (en) 1992-03-27 1994-01-11 E. R. Squibb & Sons, Inc. Process for the preparation of 1,3-dioxane derivatives useful in the preparation of HMG-COA reductase inhibitors
SG44830A1 (en) 1992-07-02 1997-12-19 Hoechst Ag Process for preparing tert-butyl 93R,5S) -6 Hydroxy-3,5-O-Isopropylidene-3, 5-Dihydroxyhexanoate
JP3197971B2 (ja) 1993-03-01 2001-08-13 塩野義製薬株式会社 ５−カルボアルコキシピリミジン誘導体の合成方法
EP0790826A4 (en) 1994-11-16 1998-11-11 Synaptic Pharma Corp DIHYDROPYRIMIDINES AND THEIR USES
DE19517186A1 (de) 1995-05-11 1996-11-14 Bayer Ag Verfahren zur Herstellung substituierter 2-Fluor-pyrimidine
US6278001B1 (en) 1995-11-28 2001-08-21 L'oréal Method for preparing (+) compactin and (+) mevinolin analog compounds having a β-hydroxy-δ-lactone grouping
FR2741620B1 (fr) 1995-11-28 1997-12-26 Oreal Procede de preparation de composes a groupement beta-hydroxy -delta-lactone analogues de la (+) compactine et de la (+) mevinoline
JP2000501734A (ja) 1995-12-14 2000-02-15 メルク エンド カンパニー インコーポレーテッド ジヒドロピリミジノンの製造方法
CA2296704C (en) * 1997-07-14 2010-10-19 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
WO1999007695A2 (en) 1997-08-05 1999-02-18 Merck & Co., Inc. ALPHA 1a ADRENERGIC RECEPTOR ANTAGONIST
JP4440476B2 (ja) 1998-12-10 2010-03-24 株式会社カネカ シンバスタチンの製造方法
GB9903472D0 (en) 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
JP4204132B2 (ja) 1999-02-19 2009-01-07 大塚化学ホールディングス株式会社 摩擦材
WO2000078730A1 (en) 1999-06-23 2000-12-28 Ajinomoto Co., Inc. Novel dihydropyrimidine derivatives
EP1194582A1 (de) 1999-07-09 2002-04-10 Forschungszentrum Jülich Gmbh Verfahren zur reduktion von keto-carbonsäuren und deren estern
US6579984B1 (en) 1999-07-13 2003-06-17 Lonza Ag Process for preparing 2-amino-4-(4-fluorphenyl)-6-alkylpyrimidine-5-carboxylate
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
WO2001072706A1 (en) 2000-03-28 2001-10-04 Biocon India Limited Synthesis of [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
GB0011120D0 (en) 2000-05-09 2000-06-28 Avecia Ltd Process
GB0011163D0 (en) * 2000-05-10 2000-06-28 Astrazeneca Ab Chemical compound
US8374574B1 (en) 2000-07-06 2013-02-12 Motorola Mobility Llc Method and apparatus for storing a message for playback during a user-initiated emergency telephone call from a wireless device
NL1015744C2 (nl) 2000-07-19 2002-01-22 Dsm Nv Werkwijze voor de bereiding van 2-(6-gesubstitueerde-1,3-dioxan-4-yl) azijnzuurderivaten.
CN1473156A (zh) 2000-11-10 2004-02-04 - 嘧啶衍生物及其作为神经肽y受体配体的用途
MXPA03011195A (es) 2001-06-06 2004-03-18 Bristol Myers Squibb Co Proceso para preparacion de sulfonas de diol quirales e inhibidores de coa-reductasa del dihidroxiacido hmg.
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
CN1610657A (zh) 2001-07-06 2005-04-27 西巴特殊化学品控股有限公司 制备用于合成他汀类衍生物、特别是7－氨基3,5－二羟基庚酸衍生物的中间体的方法,及其中间体
IL159741A0 (en) 2001-07-13 2004-06-20 Astrazeneca Uk Ltd Preparation of aminopyrimidine compounds
CA2455842A1 (en) * 2001-08-22 2003-03-06 Ciba Specialty Chemicals Holding Inc. Process for the preparation of indole derivatives
EP1323717A1 (en) 2001-12-27 2003-07-02 Dsm N.V. Process for the preparation of 2-(6-Substituted-1,3-Dioxane-4-yL) acetic acid derivatives
US6835838B2 (en) 2002-01-28 2004-12-28 Novartis Ag Process for the manufacture of organic compounds
KR100511533B1 (ko) 2002-04-09 2005-08-31 임광민 키랄 중간체, 그의 제조방법 및 그를 이용한 HMG-CoA환원저해제의 제조방법
EP1375493A1 (en) 2002-06-17 2004-01-02 Dsm N.V. Process for the preparation of an dioxane acetic acid ester
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
ATE501126T1 (de) * 2002-12-10 2011-03-15 Ranbaxy Lab Ltd Verfahren zur herstellung von rosuvastatin
ES2335279T3 (es) 2002-12-16 2010-03-24 Astrazeneca Uk Limited Procedimiento para la preparacion de compuestos de pirimidina.
WO2004103977A2 (en) 2003-05-21 2004-12-02 Ciba Specialty Chemicals Holding Inc. Process for the preparation of pyrimidine derivatives
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (es) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd Compuestos químicos
GB0321827D0 (en) 2003-09-18 2003-10-15 Astrazeneca Uk Ltd Chemical compounds
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
DE10352659B4 (de) 2003-11-11 2007-09-13 Ratiopharm Gmbh Verfahren zur Herstellung von Statinen und Tetrahydropyranonderivate zur Verwendung in dem Verfahren
WO2005054207A1 (en) 2003-12-04 2005-06-16 Glenmark Pharmaceuticals Limited Process for the preparation of pyrimidine derivatives
KR20060135712A (ko) 2003-12-24 2006-12-29 테바 파마슈티컬 인더스트리즈 리미티드 높은 ｓｙｎ형 대 ａｎｔｉ형 비율을 지닌 스타틴의 제조방법
GB0428328D0 (en) 2004-12-24 2005-02-02 Astrazeneca Uk Ltd Chemical process
CA2498978A1 (en) 2005-02-28 2006-08-28 Apotex Pharmachem Inc. An improved process for the preparation of atorvastatin and intermediates
GB0514078D0 (en) 2005-07-08 2005-08-17 Astrazeneca Uk Ltd Chemical process
TW200831469A (en) 2006-12-01 2008-08-01 Astrazeneca Uk Ltd Chemical process

Also Published As

Publication number Publication date
CA2589775A1 (en) 2006-06-29
IL183528A0 (en) 2007-09-20
JP5127460B2 (ja) 2013-01-23
WO2006067456A3 (en) 2006-09-21
WO2006067456A2 (en) 2006-06-29
NO20072872L (no) 2007-09-17
AU2005317880A1 (en) 2006-06-29
BRPI0518647A2 (pt) 2008-12-02
CN101084197A (zh) 2007-12-05
MX2007007777A (es) 2007-08-14
AU2005317880B2 (en) 2009-05-28
EP1871747A2 (en) 2008-01-02
CN101084197B (zh) 2012-06-13
US20080207903A1 (en) 2008-08-28
JP2008525407A (ja) 2008-07-17
ZA200704535B (en) 2008-11-26
GB0428328D0 (en) 2005-02-02
NZ555769A (en) 2010-01-29
US8034932B2 (en) 2011-10-11
IL183528A (en) 2012-02-29
EP2361906A1 (en) 2011-08-31

Similar Documents

Publication Publication Date Title
KR20070092307A (ko) 로수바스타틴 제조 방법
CN101218210B (zh) 罗苏伐他汀的制备方法和中间体
US20080188657A1 (en) Chemical process
WO2000049014A1 (en) Process for the production of tert-butyl (e)-(6-[2- [4-(4-fluorophenyl) -6-isopropyl-2-[ methyl (methylsulfonyl) amino] pyrimidin-5-yl] vinyl](4r, 6s)-2,2-dimethyl [1,3]dioxan-4-yl) acetate
US8394956B2 (en) Process for preparing pyrimidine propenaldehyde
WO2008072078A1 (en) An improved process for preparing rosuvastatin caclium
KR20130087153A (ko) 로수바스타틴의 제조방법 및 이에 사용되는 중간체 화합물
KR100535450B1 (ko) 피리미딘유도체의제조방법
SK222002A3 (en) Process for preparing 2-amino-4-(4-fluorphenyl)-6-alkylpyrimidine-5-carboxylate
JP3252502B2 (ja) Ｎ−５保護した２，５−ジアミノ−４，６−ジクロロピリミジンおよびその製造方法
KR20120092788A (ko) 스타틴의 중간체, 이의 제조방법 및 이를 이용한 로수바스타틴의 제조방법
HK1160468A (en) Process for preparing rosuvastatin

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20070724

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20101119

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20121012

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20130429

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20121012

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I